SEC Info - Nymox Pharmaceutical Corp

SEC Info℠

Home

Help

Please Sign In

Nymox Pharmaceutical Corp – ‘6-K’ for 3/31/20

On: Thursday, 5/14/20, at 4:40pm ET · For: 3/31/20 · Accession #: 1640334-20-1197 · File #: 1-12033

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/14/20  Nymox Pharmaceutical Corp         6-K         3/31/20   40:1.4M                                   Pubco Reporting … Inc/FA

Report by a Foreign Issuer — Form 6-K — Rule 13a-16 / 15d-16
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report by a Foreign Issuer                          HTML     18K 
 2: EX-99.1     Quarterly Report for the Quarter Ended March31,     HTML    158K 
                2020                                                             
 3: EX-99.2     CEO Certifications                                  HTML     21K 
 4: EX-99.3     CFO Certifications                                  HTML     21K 
29: R1          Document and Entity Information                     HTML     27K 
13: R2          Consolidated Statements of Operations (Unaudited)   HTML     61K 
23: R3          Consolidated Statements of Financial Position       HTML     74K 
33: R4          Consolidated Statements of Financial Position       HTML     15K 
                (Parenthetical)                                                  
30: R5          Consolidated Statements of Cash Flows (Unaudited)   HTML     65K 
14: R6          Consolidated Statements of Changes in Equity        HTML     41K 
                (Unaudited)                                                      
24: R7          Basis of preparation                                HTML     21K 
34: R8          Liquidity, Going Concern and Management?s Response  HTML     17K 
28: R9          Share capital                                       HTML     54K 
37: R10         Earnings per share                                  HTML     22K 
26: R11         Operating lease and other commitments               HTML     28K 
16: R12         Related Party Transactions                          HTML     25K 
18: R13         Subsequent events                                   HTML     15K 
38: R14         Share capital (Tables)                              HTML     46K 
27: R15         Earnings per share (Tables)                         HTML     21K 
17: R16         Operating lease and other commitments (Tables)      HTML     25K 
19: R17         Related Party Transactions (Tables)                 HTML     21K 
40: R18         Share capital (Details)                             HTML     37K 
25: R19         Share capital (Details 1)                           HTML     21K 
11: R20         Share capital (Details 2)                           HTML     18K 
20: R21         Share capital (Details Narrative)                   HTML     26K 
35: R22         Earnings per share (Details)                        HTML     20K 
31: R23         Operating lease and other commitments (Details)     HTML     18K 
12: R24         Operating lease and other commitments (Details 1)   HTML     23K 
21: R25         Operating lease and other commitments (Details      HTML     25K 
                Narrative)                                                       
36: R26         Related Party Transactions (Details)                HTML     24K 
32: R27         Related Party Transactions (Details Narrative)      HTML     19K 
39: XML         IDEA XML File -- Filing Summary                      XML     64K 
22: EXCEL       IDEA Workbook of Financial Reports                  XLSX     29K 
 5: EX-101.INS  XBRL Instance -- nymx-20200331                       XML    368K 
 7: EX-101.CAL  XBRL Calculations -- nymx-20200331_cal               XML     69K 
 8: EX-101.DEF  XBRL Definitions -- nymx-20200331_def                XML    131K 
 9: EX-101.LAB  XBRL Labels -- nymx-20200331_lab                     XML    357K 
10: EX-101.PRE  XBRL Presentations -- nymx-20200331_pre              XML    262K 
 6: EX-101.SCH  XBRL Schema -- nymx-20200331                         XSD    108K 
15: ZIP         XBRL Zipped Folder -- 0001640334-20-001197-xbrl      Zip     41K

‘6-K’ — Report by a Foreign Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the period ended March 31, 2020

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): ¨

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby

furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______________

Exhibits

99.1		Quarterly Report for the Quarter ended March31, 2020
99.2		CEO Certifications
99.3		CFO Certifications

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NYMOX PHARMACEUTICAL CORPORATION
	(Registrant)

	By:	/s/ *Paul Averback, MD*
	Paul Averback, MD
	President and Chief Executive Officer

Date: May 14, 2020

Dates Referenced Herein

This ‘6-K’ Filing	Date	Other Filings

Filed on:	5/14/20	None on these Dates
For Period end:	3/31/20
		List all Filings

↑Top

Filing Submission 0001640334-20-001197 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)